Intraperitoneal chemotherapy and immunotherapy.
1. The predictive model is validated empirically; a kinetic advantage for i.p. administration of certain antineoplastic drugs exist. 2. The concentrations achieved in the peritoneum are orders of magnitude greater than those found in the plasma, so rate-limiting systemic toxicities may be avoided. 3. The aspirin principle--if one is good, two are better--may not be applicable unless we can utilize this advantage to improve survival.
D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000493:pharmacokinetics; D005260:Female; D005770:Gastrointestinal Neoplasms / Q000188:drug therapy / Q000628:therapy*; D006801:Humans; D007167:Immunotherapy; D007274:Injections, Intraperitoneal; D008954:Models, Biological; D010051:Ovarian Neoplasms / Q000188:drug therapy / Q000628:therapy*
D000970:Antineoplastic Agents